Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron adjunctive therapy in residual schizophrenia
IRCT20120314009297N7Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ondansetron in schizophrenia (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: PANSS total and symptom severity assessment, CGI-S severity assessment and 6 more. Started May 2020; status: completed.
02
Drugs
ondansetron
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20120314009297N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120314009297N7.